vTv Therapeutics (NASDAQ:VTVT) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT - Free Report) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the biotechnology company's stock.

Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They issued a "buy" rating and a $35.00 price target for the company.

vTv Therapeutics Trading Up 1.2 %

Shares of VTVT traded up $0.20 during midday trading on Thursday, reaching $17.35. The stock had a trading volume of 5,294 shares, compared to its average volume of 22,807. The company has a market capitalization of $55.35 million, a price-to-earnings ratio of -3.83 and a beta of 1.07. The company's 50-day moving average is $17.32 and its 200 day moving average is $15.53. vTv Therapeutics has a 12-month low of $12.12 and a 12-month high of $29.19.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.32. The firm had revenue of $0.02 million during the quarter.

Hedge Funds Weigh In On vTv Therapeutics

Large investors have recently bought and sold shares of the stock. FMR LLC purchased a new stake in shares of vTv Therapeutics during the third quarter valued at approximately $2,402,000. JPMorgan Chase & Co. bought a new stake in vTv Therapeutics during the 4th quarter valued at $25,000. Finally, Geode Capital Management LLC boosted its position in vTv Therapeutics by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after buying an additional 1,327 shares during the period. 17.51% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.